NCT00971035

A Study to Evaluate Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Not Taking Inhaled Corticosteroids

A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Not Taking Inhaled Corticosteroids (MOLLY)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 210 (actual)
• Sponsor: Genentech, Inc. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized, double-blind, placebo controlled, four-arm, dose-ranging study. The purpose is to evaluate the relationship between the dose of lebrikizumab and the response in terms of the efficacy, safety, and tolerability in patients with asthma who are not on inhaled steroids.

Conditions

• Asthma

Interventions

Type	Name	Description
DRUG	lebrikizumab (MILR1444A)	Subcutaneous repeating dose
DRUG	lebrikizumab (MILR1444A)	Subcutaneous repeating dose
DRUG	lebrikizumab (MILR1444A)	Subcutaneous repeating dose
DRUG	placebo	Subcutaneous repeating dose

Timeline

• Start date: 2009-11-01
• Primary completion: 2010-12-01
• Completion: 2011-02-01
• First posted: 2009-09-03
• Last updated: 2016-11-29